Publications by authors named "Dimitrios Ioannides"
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.
Dermatol Ther (Heidelb)
July 2025
Introduction: Hidradenitis suppurativa (HS) is a chronic, painful skin disease associated with a high disease burden. Disease-related pain is frequently reported as the most troublesome symptom of HS. The SUNSHINE and SUNRISE phase 3 trials previously reported that secukinumab improved control of pain in patients with moderate to severe HS.
View Article and Find Full Text PDFManagement of folliculitis decalvans: The EADV task force on hair diseases position statement.
J Eur Acad Dermatol Venereol
August 2025
Folliculitis decalvans is the most common form of primary neutrophilic scarring alopecia, which is diagnosed in 2.8% of patients with hair loss. The course of the disease is typically chronic and relapsing.
View Article and Find Full Text PDFDelphi Consensus on the Distinct Clinical and Histopathological Features of Lichen Planopilaris and Frontal Fibrosing Alopecia: Insights From the Hair Diseases EADV Task Force.
Int J Dermatol
July 2025
Background: Frontal fibrosing alopecia (FFA) has been defined as a lichen planopilaris (LPP) variant, and both are characterized by lymphocytic scarring alopecia. Despite histopathological similarities, they differ clinically, suggesting potentially different pathogenetic factors. This Delphi study aimed to collect expert opinions to clarify the relationship between FFA and LPP.
View Article and Find Full Text PDFThe purpose of this study was to evaluate the quality of life (QoL) and psychosocial burden in adult Greek patients with atopic dermatitis (AD) using validated tools and to investigate factors that influence AD's humanistic burden. This observational, cross-sectional study was conducted in Greece (January-September 2023) with 150 adult members of the patient association "EPIDERMIA", all diagnosed with AD. Data was collected via a structured questionnaire, including socio-demographic details, clinical history, AD severity (using the Patient-Oriented Eczema Measure [POEM]), QoL, sleep disorders, and psychological health.
View Article and Find Full Text PDFArticle Synopsis
- Inconsistent reporting of outcomes in rosacea clinical trials is hindering accurate data analysis and meta-analyses, highlighting the need for standardized outcome measures.
- A core outcome set (COS) was developed through systematic literature reviews and a Delphi process, involving feedback from physicians and patients to identify essential outcomes in rosacea trials.
- The final COS includes 8 key domains, such as skin symptoms and patient satisfaction, which aim to enhance the comparability and relevance of future rosacea research and interventions.
Article Synopsis
- Linear IgA Dermatosis (LAD) is a rare autoimmune skin disease characterized by IgA deposits at the skin's basement membrane, affecting both children and adults with diverse clinical features.
- The European Academy of Dermatology and Venereology (EADV) developed consensus guidelines by collaborating with 29 experts across multiple countries to ensure a comprehensive approach to diagnosis and treatment.
- The resulting guidelines provide a combination of evidence-based and expert-based recommendations to aid dermatologists in effectively diagnosing and managing LAD.
: Dermatoscopy has been established as an important diagnostic tool for a wide range of skin diseases. This study aims to evaluate the use of dermatoscopy in clinical practice among Greek dermatologists. : A nationwide questionnaire-based survey was conducted collecting data on the frequency of dermatoscopic examinations, the types of lesions examined, training and educational resources, as well as factors influencing the choice to incorporate dermatoscopy into daily clinical routines.
View Article and Find Full Text PDFReal-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
J Eur Acad Dermatol Venereol
June 2024
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment
Article Synopsis
- * Despite a good prognosis, cSCC leads to many deaths because of its high occurrence, highlighting the importance of ongoing research and treatment recommendations.
- * A group of experts from various European dermatological and oncology organizations has come together to update guidelines on cSCC, focusing on various aspects such as classification, diagnosis, risk factors, and prevention for both immunocompetent and immunosuppressed individuals.
Article Synopsis
- A multidisciplinary panel of experts from various European medical organizations has developed updated recommendations for treating invasive cutaneous squamous cell carcinoma (cSCC) based on a thorough literature review and expert consensus.
- Treatment guidelines cover different stages of cSCC, recommending surgery with clear margins as the primary option for low and high-risk cases, while highlighting the lack of benefit from radiation for high-risk patients with clear margins.
- For advanced cSCC that cannot be surgically treated, anti-PD-1 agents like cemiplimab are recommended as first-line therapy, with second-line options including cetuximab combined with chemotherapy or radiation.
Metformin in Hidradenitis Suppurativa: Is It Worth Pursuing Further?
Skin Appendage Disord
June 2023
Article Synopsis
- * A systematic review analyzed data from six studies involving 133 patients treated with metformin for HS, mostly featuring overweight or obese women in their thirties.
- * Results showed that while many patients experienced improvements, outcomes varied; metformin was generally well tolerated with only mild side effects, suggesting more rigorous trials against placebo could be valuable.
Article Synopsis
- The study examines the management of basal cell carcinoma (BCC) that has been incompletely excised, highlighting different treatment approaches and their effectiveness in a tertiary dermatology center in Northern Greece.
- Researchers analyzed 84 patients with incompletely excised BCC over a 5-year period and categorized them into three groups: immediate re-excision, watchful waiting, and non-surgical treatments.
- Results showed that re-excision resulted in residual tumor presence in over half of the cases and clinical recurrence occurred in 16.7% of patients, suggesting that the management strategy chosen can significantly impact outcomes.
Article Synopsis
- Patients with serious comorbidities are often left out of clinical trials, but apremilast is not contraindicated for these conditions, necessitating real-world data to validate its safety and efficacy.
- This study aimed to provide real-world evidence regarding the use of apremilast in psoriasis patients with significant comorbidities, utilizing a case-series approach and a systematic literature review.
- Results indicated that among 841 patients treated with apremilast, only a few cases of cancer progression were noted, with no adverse effects leading to infections or worsening of comorbidities, suggesting it is a safe treatment alternative for difficult-to-treat psoriasis patients.
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Dermatol Ther
December 2022
Article Synopsis
- Brodalumab has shown significant clinical effectiveness and a good safety record in controlled trials, but limited real-world data exists; the BrIDGE study in Greece aims to fill this gap by observing treatment outcomes in moderate-to-severe plaque psoriasis patients over 104 weeks.* -
- Early results from the study, covering 12-16 weeks post-treatment initiation, indicate that 72.8% of patients achieved a "clear/almost clear" skin rating, with varying percentages reaching significant reductions in psoriasis severity scores (PASI75, PASI90, PASI100).* -
- Improvements in symptoms and quality of life were noted alongside a high treatment adherence rate of 90%, and while nine adverse events were recorded, the
Die Daten zu Hidradenitis suppurativa (HS)-bedingten Kosten sind begrenzt und inhomogen. Sie sind jedoch erheblich. Wir führten eine systematische Sichtung der Literaturberichte durch, in denen finanzielle Daten über jeden Gesundheitsbereich oder andere Ausgaben dokumentiert wurden, die durch HS und/oder HS-bedingte Auswirkungen auf Beschäftigung, Einkommen und persönliches wirtschaftliche Entwicklung entstanden sind (indirekte Kosten).
View Article and Find Full Text PDFExtensive acquired macular hyperpigmentation in a teenager.
Clin Exp Dermatol
October 2022
A teenage girl with phototype IV skin presented with extensive gradually progressing asymptomatic macular hyperpigmentation not responding to topical steroids for several months. Histopathology showed foci of increased numbers of melanophages and melanin in the dermis. Click here for the corresponding questions to this CME article.
View Article and Find Full Text PDFData regarding hidradenitis suppurativa (HS)-related expenditure is limited and non-homogeneous, but HS does incur significant expenses. We performed a systematic review of literature reports documenting financial data regarding any healthcare domain or other expenditure incurred by HS and/or HS impact on work, income and personal economic growth (indirect costs). Three electronic databases were searched (MEDLINE, ScienceDirect, and the Cochrane Library - last search date: September 14 , 2021).
View Article and Find Full Text PDFIntroduction: Drug survival is an indirect measure of efficacy and safety and its post-marketing assessment using real-life data is invaluable.
Objectives: To investigate the survival of apremilast in a cohort of psoriasis patients treated with apremilast in a Greek hospital.
Methods: A retrospective cross-sectional study examined adult psoriasis patients receiving apremilast (March 2016 to January 2021).
Article Synopsis
- Pain from hidradenitis suppurativa (HS) drastically affects patients' quality of life, and finding effective management strategies remains a challenge.
- Adalimumab, a TNF-a antagonist, has shown promising results in reducing pain associated with HS, as evidenced by a significant mean pain score reduction in a meta-analysis of multiple studies.
- The findings support the broader prescription of adalimumab for patients with HS who experience significant pain, indicating its potential as an effective treatment option.
Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population.
Dermatol Ther
June 2022
Article Synopsis
- - The CELSUS study in Greece evaluated the effectiveness of Calcipotriol/Betamethasone (Cal/BD) aerosol foam for psoriasis treatment and found it led to significant patient satisfaction and treatment success across various disease severities.
- - Out of 400 patients, those naïve to treatment had better success rates (72.6% for mild, 56.5% for moderate, and 66.7% for severe) compared to treatment-experienced patients (60.7%, 42.2%, and 25% respectively) after 4 weeks.
- - Overall, both treatment-naïve and treatment-experienced patients showed notable reductions in psoriasis symptoms, with the most significant improvements seen
Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis.
View Article and Find Full Text PDFBackground: Blue color in dermoscopy can be seen in a wide range of benign and malignant lesions, melanocytic or not. Some blue-colored dermoscopic criteria have been associated with specific tumors, such as blue-white veil with melanoma and homogeneous blue with blue nevi. However, when blue color occupies a large part of the lesion's surface, the dermoscopic assessment might be particularly challenging.
View Article and Find Full Text PDF